Review the ECLIPSE study published in New England Journal of Medicine.  See the data

Test tube for blood-based screening.

Blood-based screening for colorectal cancer (CRC) fits right in

Increase CRC screening compliance with a simple blood draw at any patient visit.1

Accurate blood-based screening.1 Simply done.

75% of people who died from CRC were not up to date with screening2
Patients who are not up to date with screening are at increased risk of CRC mortality2CRC remains the second-leading cause of cancer-related deaths in the United States.3 Breaking down barriers and getting patients screened is more crucial than ever.4 See CRC screening barriers
ShieldTM is an accurate blood test that removes CRC screening barriers1,5-9 Explore how
Guardant Health logo

Guardant Health has advanced our technology to include screening for early CRC detection5,9

We are dedicated to supporting patients with cancer across the continuum of care. NCI and NCCN cancer centers use Guardant Health’s existing blood-based tests to inform treatment decisions for patients with early- and late-stage cancer.10 Guardant Health is now leveraging the same technology for a blood test that detects CRC early, when it’s more treatable.3,5,9 See our expanding legacy

Sign up to receive the latest updates on ShieldTM

By clicking the button above, you agree to receive periodic product-related updates via email from Guardant Health.

A1C=glycated hemoglobin; CBC=complete blood count; NCI=National Cancer Institute; NCCN=National Comprehensive Cancer Network; TSH=thyroid-stimulating hormone.
Shield™ is a qualitative laboratory developed test intended to detect colorectal cancer by identifying genomic and epigenomic alterations in cell-free DNA in plasma from blood collected in Guardant blood collection tubes.
  • The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
  • Patients with an "abnormal signal detected" Shield test result should be referred for colonoscopic evaluation
  • A "normal signal detected" Shield test result does not preclude the presence of colorectal cancer, and patients should continue participating in guideline-recommended screening programs
  • Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA
References 1. Chung DC, Gray DM II, Singh H, et al. A cell-free DNA blood-based test for colorectal cancer screening. N Engl J Med. 2024;390(11):973-983. doi:10.1056/NEJMoa2304714 2. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156(1):63-74. doi:10.1053/j.gastro.2018.09.040 3. American Society of Clinical Oncology. Colorectal cancer: statistics. website. Updated January 2021. Accessed May 10, 2021. 4. Davidson KW, Barry MJ, Mangione CM, et al; US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2021;325(19):1965-1977. doi:10.1001/jama.2021.6238 5. Kim ST, Raymond VM, Park JO, et al. Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC). Cancer Res. 2019;79(suppl 13):916. doi:10.1158/1538-7445.AM2019-916 6. Liles EG, Coronado GD, Perrin N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: a randomized trial. Cancer Treat Res Comm. 2017;10:27-31. doi:10.1016/j.ctarc.2016.12.004 7. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med. 2005;20(11):989-995. doi:10.1111/j.1525-1497.2005.00164.x 8. Parks P. Innovation in colorectal cancer screening - there has to be a better way. Am J Manag Care. Published October 9, 2017. Accessed September 17, 2021. 9. Westesson O, Axelrod H, Dean J, et al. Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer. Cancer Res. 2020;80(suppl 16):2316. doi:10.1158/1538-7445.AM2020-2316 10. Data on file. Guardant Health, Inc.